Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
US11634488B2 · kind B2 · utility
0Cited by
74References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2018 |
| Grant date | Apr 25, 2023 |
| Priority date | — |
| Expiry date | Mar 10, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/734
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.